Cargando…

HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues

HLA-F belongs to the non-classical HLA-Ib molecules with a marginal polymorphic nature and tissue-restricted distribution. HLA-F is a ligand of the NK cell receptor KIR3DS1, whose activation initiates an antiviral downstream immune response and lead to delayed disease progression of HIV-1. During th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hò, Gia-Gia T., Heinen, Funmilola J., Huyton, Trevor, Blasczyk, Rainer, Bade-Döding, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525141/
https://www.ncbi.nlm.nih.gov/pubmed/30941482
http://dx.doi.org/10.1007/s00251-019-01112-1
_version_ 1783419663143665664
author Hò, Gia-Gia T.
Heinen, Funmilola J.
Huyton, Trevor
Blasczyk, Rainer
Bade-Döding, Christina
author_facet Hò, Gia-Gia T.
Heinen, Funmilola J.
Huyton, Trevor
Blasczyk, Rainer
Bade-Döding, Christina
author_sort Hò, Gia-Gia T.
collection PubMed
description HLA-F belongs to the non-classical HLA-Ib molecules with a marginal polymorphic nature and tissue-restricted distribution. HLA-F is a ligand of the NK cell receptor KIR3DS1, whose activation initiates an antiviral downstream immune response and lead to delayed disease progression of HIV-1. During the time course of HIV infection, the expression of HLA-F is upregulated while its interaction with KIR3DS1 is diminished. Understanding HLA-F peptide selection and presentation is essential to a comprehensive understanding of this dynamic immune response and the molecules function. In this study, we were able to recover stable pHLA-F*01:01 complexes and analyze the characteristics of peptides naturally presented by HLA-F. These HLA-F-restricted peptides exhibit a non-canonical length without a defined N-terminal anchor. The peptide characteristics lead to a unique presentation profile and influence the stability of the protein. Furthermore, we demonstrate that almost all source proteins of HLA-F-restricted peptides are described to interact with HIV proteins. Understanding the balance switch between HLA-Ia and HLA-F expression and peptide selection will support to understand the role of HLA-F in viral pathogenesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00251-019-01112-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6525141
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-65251412019-06-05 HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues Hò, Gia-Gia T. Heinen, Funmilola J. Huyton, Trevor Blasczyk, Rainer Bade-Döding, Christina Immunogenetics Original Article HLA-F belongs to the non-classical HLA-Ib molecules with a marginal polymorphic nature and tissue-restricted distribution. HLA-F is a ligand of the NK cell receptor KIR3DS1, whose activation initiates an antiviral downstream immune response and lead to delayed disease progression of HIV-1. During the time course of HIV infection, the expression of HLA-F is upregulated while its interaction with KIR3DS1 is diminished. Understanding HLA-F peptide selection and presentation is essential to a comprehensive understanding of this dynamic immune response and the molecules function. In this study, we were able to recover stable pHLA-F*01:01 complexes and analyze the characteristics of peptides naturally presented by HLA-F. These HLA-F-restricted peptides exhibit a non-canonical length without a defined N-terminal anchor. The peptide characteristics lead to a unique presentation profile and influence the stability of the protein. Furthermore, we demonstrate that almost all source proteins of HLA-F-restricted peptides are described to interact with HIV proteins. Understanding the balance switch between HLA-Ia and HLA-F expression and peptide selection will support to understand the role of HLA-F in viral pathogenesis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00251-019-01112-1) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2019-04-02 2019 /pmc/articles/PMC6525141/ /pubmed/30941482 http://dx.doi.org/10.1007/s00251-019-01112-1 Text en © The Author(s) 2019, corrected publication 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Hò, Gia-Gia T.
Heinen, Funmilola J.
Huyton, Trevor
Blasczyk, Rainer
Bade-Döding, Christina
HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
title HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
title_full HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
title_fullStr HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
title_full_unstemmed HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
title_short HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues
title_sort hla-f*01:01 presents peptides with n-terminal flexibility and a preferred length of 16 residues
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525141/
https://www.ncbi.nlm.nih.gov/pubmed/30941482
http://dx.doi.org/10.1007/s00251-019-01112-1
work_keys_str_mv AT hogiagiat hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues
AT heinenfunmilolaj hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues
AT huytontrevor hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues
AT blasczykrainer hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues
AT badedodingchristina hlaf0101presentspeptideswithnterminalflexibilityandapreferredlengthof16residues